anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background & objectives Neuronal hypoxia associated with conditions like traumatic brain injury and cardiac tachyarrhythmia has been implicated in causing hypopituitarism. Individuals with complete heart block (CHB) may be predisposed to develop anterior pituitary hormone dysfunction in the long term. The objective of this study was to investigate anterior pituitary hormone functions in individuals after CHB. Methods This prospective cohort study included 30 individuals (21 men and 9 women) with CHB requiring pacemaker implantation, who were evaluated at admission and then at a mean follow up of 12.4 ± 2.2 months to look for development of any degree of hypopituitarism. In addition to the measurement of hormones like follicle-stimulating hormone (FSH), luteinising hormone (LH), thyroid stimulating hormone (TSH), total tetra iodothyronines (TT4), free tetraiodothyronines (FT4), cortisol, insulin-like growth factor-1 (IGF-1), testosterone and estradiol, a fixed-dose glucagon stimulation test (GST) was performed to assess growth hormone (GH) and adrenocorticotrophic hormone (ACTH) axis. Results The mean age of the participants was 64.9 ± 11.3 yr. At follow up evaluation, 17 (56.7%) had low serum IGF-1, and among them, seven (23%) had growth hormone deficiency (GHD) (peak GH <1.0 ng/ml after GST). Six participants (20%) had ACTH deficiency (peak cortisol <9 ug/dl after GST) and one had TSH deficiency. None had prolactin (PRL) or gonadotropin deficiency. Overall, hormone deficiencies were observed in nine patients (30%). Interpretation & conclusions This pilot study detected loss of anterior pituitary hormones in a significant number of individuals of CHB at 12 months follow up. Unrecognised hypopituitarism may have resulted in significant morbidity and mortality in these individuals.
A 6-week home-based remote supervision cardiac rehabilitation programme with an I-CREST application and smartwatch. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
Noninvasive monitoring of liver fibrosis is an unmet and critical need within the clinical management of children with chronic liver disease. While liver biopsy is often used in the initial diagnostic evaluation of children with liver disease, subsequent surveillance liver biopsy is rarely performed in children because of its inherent invasiveness and risks. Therefore, our understanding of the natural history of fibrosis progression in children is limited. The patchy nature of fibrosis in many important pediatric liver diseases \[e.g. biliary atresia (BA) and cystic fibrosis liver disease (CFLD)\] limits the utility of sequential liver biopsy even if it were to be employed in clinical practice in pediatrics. Thus, non-invasive means of assessing liver fibrosis throughout the liver would be highly desirable and clinically useful in pediatric hepatology. ChiLDReN is poised and uniquely qualified to conduct a comprehensive longitudinal assessment of the utility of FibroScan™-specific elastography, liver stiffness measurement (LSM) as a measure of hepatic fibrosis in children with serious chronic cholestatic liver disease.
Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
Endoscopic treatment using the HALO® 360 or 90 system is a thermal ablation system for superficial mucosa. First and foremost, the examination includes an endoscopy to locate the upper limits of the BE and its distribution, so as to choose the most appropriate type of probe. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.
<P>PROBLEM TO BE SOLVED: To provide a method for producing organic plate particles having moderately lowered gloss and suitable as particles for the production of cosmetics and industrial particles for the production of coloring materials, water-based inks, etc.  <P>SOLUTION: The method for the production of organic plate particles comprises the use of an organic layer transfer sheet at least having a mat layer and an organic layer on a substrate, the thermal transfer of the organic layer to a transfer object, the peeling of the organic layer and the crushing of the peeled layer. The other method for the production of organic plate particles comprises the thermal transfer of an organic layer in an arbitrary shape by using a thermal head and the peeling of the transferred organic layer. The organic layer is composed mainly of a thermoplastic resin or a wax. The transfer object has an average surface roughness Ra (in conformity to JIS-0601-1994) of 0.1-1.5 μm. An adhesive layer is formed on the organic layer as needed.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The incidence of autism spectrum disorders (ASD) has increased dramatically in the last decade. The latest report from the Centers for Disease Control and Prevention state that 1 in 59 children are being diagnosed with ASD and it is four times more prevalent in boys than girls. Common treatments for children with ASD are applied behavioral therapy, occupational and speech therapy, which are used solely or in combination. Hippotherapy (HPOT) is another treatment option that has been shown to positively impact various aspects of behavior. This pilot project aims to determine the effects of a 6-week HPOT program on movement and social behavior of children with ASD and to investigate the underlying mechanisms of why HPOT is successful for ASD through the coupling of physiological and temperamental responses between horse and rider. The approach involves examining these skills pre, during, and post HPOT intervention in children diagnosed with ASD. A group of aged matched children with typical development will serve as the control group. Innovative measures of physiological coupling and temperament between horse and rider as well as objective and quantitative measures of movement and social behavior and caregiver perception will be collected. The investigators anticipate that following completion of the proposed study, they will provide the necessary foundation to understand the mechanisms of HPOT, and thus provide a new framework to test clinical trials of HPOT and human-animal interaction, and ultimately improve the lives of those diagnosed with ASD and their families.
BACKGROUND: Nursing occupational fatigue has emerged as a critical issue affecting the safety and health of nurses. This phenomenon not only impairs nurses' performance and mental well-being but also poses risks to patient safety and the quality of care provided. This study focuses on endoscopic nurses to explore the mediating role of positive coping styles between sleep quality and occupational fatigue, aiming to identify effective strategies to alleviate fatigue, thereby improving the work environment and enhancing healthcare quality.
METHODS: From July to August 2023, a cross-sectional design was used to select 258 endoscopy nurses from 25 top-three hospitals in 14 cities across 5 provinces in China. Data was collected through general information questionnaires, Fatigue assessment instrument, Pittsburgh sleep quality index, and Simple Coping Style Questionnaire. A structural equation model of sleep quality - positive coping style - occupational fatigue was constructed using Amos 26.0, and Bootstrap was employed to test the mediating effect.
RESULTS: The results showed that the mean scores of sleep quality, occupational fatigue, and positive coping style for endoscopy nurses were 8.89 ± 4.13, 17.73 ± 5.64, and 18.32 ± 10.46, respectively. Positive coping style were negatively correlated with sleep quality and occupational fatigue (p < 0.001). Positive coping style partially mediated the relationship between sleep quality and occupational fatigue, with a mediating effect value of 0.253, accounting for 42.10% of the total effect.
CONCLUSION: Sleep quality can indirectly affect the level of occupational fatigue through positive coping style. Nursing managers should enhance nurses' positive coping skills, improve nurses' sleep quality, and reduce occupational fatigue among nurses.
Neurodevelopmental disorders (NDDs) are polygenic in nature and copy number variants (CNVs) are ideal candidates to study the nature of this polygenic risk. The disruption of striatal circuits is considered a central mechanism in NDDs. The 16p11.2 hemi-deletion (16p11.2 del/+) is one of the most common CNVs associated with NDD, and 16p11.2 del/+ mice show sex-specific striatum-related behavioral phenotypes. However, the critical genes among the 27 genes in the 16p11.2 region that underlie these phenotypes remain unknown. Previously, we applied a novel strategy to identify candidate genes associated with the sex-specific phenotypes of 16p11.2 del/+ mice and highlighted three genes within the deleted region: thousand and one amino acid protein kinase 2 (Taok2), seizure-related 6 homolog-like 2 (Sez6l2), and major vault protein (Mvp). Using CRISPR/Cas9, we generated mice carrying null mutations in Taok2, Sez6l2, and Mvp (3 gene hemi-deletion (3g del/+)). Hemi-deletion of these 3 genes recapitulates sex-specific behavioral alterations in striatum-dependent behavioral tasks observed in 16p11.2 del/+ mice, specifically male-specific hyperactivity and impaired motivation for reward seeking. Moreover, RNAseq analysis revealed that 3g del/+ mice exhibit gene expression changes in the striatum similar to 16p11.2 del/+ mice exclusively in males. Subsequent analysis identified translation dysregulation and/or extracellular signal-regulated kinase signaling as plausible molecular mechanisms underlying male-specific, striatum-dependent behavioral alterations. Interestingly, ribosomal profiling supported the notion of translation dysregulation in both 3g del/+ and 16p11.2 del/+ male mice. However, mice carrying a 4-gene deletion (with an additional deletion of Mapk3) exhibited fewer phenotypic similarities with 16p11.2 del/+ mice. Together, the mutation of 3 genes within the 16p11.2 region phenocopies striatal sex-specific phenotypes of 16p11.2 del/+ mice. These results support the importance of a polygenic approach to study NDDs and underscore that the effects of the large genetic deletions result from complex interactions between multiple candidate genes.
Emerging evidence has suggested that exposure to PM2.5 is a significant contributing factor to the development of chronic obstructive pulmonary disease (COPD). However, the underlying biological effects and mechanisms of PM2.5 in COPD pathology remain elusive. In this study, we aimed to investigate the implication and regulatory effect of biomass fuels related-PM2.5 (BRPM2.5) concerning the pathological process of fibroblast-to-myofibroblast transition (FMT) in the context of COPD. In vivo experimentation revealed that exposure to biofuel smoke was associated with airway inflammation in rats. After 4 weeks of exposure, there was inflammation in the small airways, but no significant structural changes in the airway walls. However, after 24 weeks, airway remodeling occurred due to increased collagen deposition, myofibroblast proliferation, and tracheal wall thickness. In vitro, cellular immunofluorescence results showed that with stimulation of BRPM2.5 for 72 h, the cell morphology of fibroblasts changed significantly, most of the cells changed from spindle-shaped to star-shaped irregular, α-SMA stress fibers appeared in the cytoplasm and the synthesis of type I collagen increased. The collagen gel contraction experiment showed that the contractility of fibroblasts was enhanced. The expression level of TRPC1 in fibroblasts was increased. Specific siRNA-TRPC1 blocked BRPM2.5-induced FMT and reduced cell contractility. Additionally, specific siRNA-TRPC1 resulted in a decrease in the augment of intracellular Ca2+ concentration ([Ca2+]i) induced by BRPM2.5. Notably, it was found that the PI3K inhibitor, LY294002, inhibited enhancement of AKT phosphorylation level, FMT occurrence, and elevation of TRPC1 protein expression induced by BRPM2.5. The findings indicated that BRPM2.5 is capable of inducing the FMT, with the possibility of mediation by PI3K/AKT/TRPC1. These results hold potential implications for the understanding of the molecular mechanisms involved in BRPM2.5-induced COPD and may aid in the development of novel therapeutic strategies for pathological conditions characterized by fibrosis.
AIM: Knowledge of risk factors may provide strategies to reduce the high burden of delirium in intensive care unit (ICU) patients. We aimed to compare the risk of delirium after deep sedation with propofol versus midazolam in ICU patients.
METHODS: In this prospective cohort study, ICU patients who were in an unarousable state for ≥24 h due to continuous sedation with propofol and/or midazolam were included. Patients admitted ≤24 h, those with an acute neurological disorder and those receiving palliative sedation were excluded. ICU patients were assessed daily for delirium during the 7 days following an unarousable state due to continuous sedation.
RESULTS: Among 950 included patients, 605 (64%) subjects were delirious during the 7 days after awaking. The proportion of subsequent delirium was higher after midazolam sedation (152/207 [73%] patients) and after both propofol and midazolam sedation (257/377 [68%] patients), compared to propofol sedation only (196/366 [54%] patients). Midazolam sedation (adjusted cause-specific hazard ratio [adj. cause-specific HR] 1.32, 95% confidence interval [CI] 1.05-1.66) and propofol and midazolam sedation (adj. cause-specific HR 1.29, 95% CI 1.06-1.56) were associated with a higher risk of subsequent delirium compared to propofol sedation only.
CONCLUSION: This study among sedated ICU patients suggests that, compared to propofol sedation, midazolam sedation is associated with a higher risk of subsequent delirium. This risk seems more apparent in patients with high cumulative midazolam intravenous doses. Our findings underpin the recommendations of the Society of Critical Care Medicine Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guidelines to use propofol over benzodiazepines for sedation in ICU patients.
FIELD: medicine, neurology. SUBSTANCE: method involves prescription of instenon-forte in the dose 1/2 of dragee, 2 times per a day for 30 days, actoprotector bemithyl in the dose 0.005 g/kg per a day for 30 days. Also, amplipulse-phoresis with proserine is carried out on antebrachii and shank limbs, 15 procedures for a course. In further, bemithyl is prescribed in the dose 1/2 of daily one for 45-60 days. Method provides to increase motional ability of patient, prolonged remission, to delay disease progression, to exclude adverse effects and to decrease time treatment in hospital. EFFECT: enhanced effectiveness of treatment. 4 ex
The invention belongs to the field of pharmaceutical preparations, and in particular relates to a long-acting co-carried hydrogel preparation for pulmonary arterial hypertension treatment, and a preparation method and application thereof. A long-acting co-carried hydrogel is characterized in that a biological macromolecular drug phospholipid compound and a micromolecular chemical drug are co-carried in an in-situ temperature-sensitive hydrogel, and an in-situ hydrogel skeleton is poloxamer. The invention improves the stability of biological macromolecules by preparing the phospholipid complex, and then loads the biological macromolecule phospholipid complex and the micromolecular compound into the in-situ temperature-sensitive hydrogel. The long-acting co-carried hydrogel can improve the stability of biological macromolecular drugs, and can be released in vivo for a long time after administration. The prepared long-acting co-carried hydrogel can simultaneously deliver biological macromolecular drugs and small molecular compounds and cooperatively treat pulmonary hypertension. The long-acting treatment of pulmonary hypertension is realized through single intramuscular injection administration, the defect of implanted pump administration is overcome, and the compliance and the living convenience of patients are expected to be improved.
The invention discloses an external plaster for pediatric deficiency cold and preparation method thereof. Aim at the physiological and pathological characteristics of children and the pathogenic factors and pathogenesis of pediatric deficiency cold, 8 Chinese crude drugs ccontaining white atractylodes rhizome, clove, chinese magnoliaving, nutmeg and so on, is processed by decocting, condensing, crushing, concocting and the other steps to form plaster. The inventive plaster has functions of invigorating qi and yang, supplementing huo and eliminating han. The principle indications are pediatric deficiency cold, sickness, hiccup, diarrhea, cllic, cough, night cry, enuresis, pale complexion, coldness of the body and limbs, tiredness, inappetence, pale lips, whitish tongue and thin white tongue, etc. The external plaster is safe and convenient in use, with remarkable effect. It solves the probleme of fearing the needle and repelling the drugs of the children, furthermore convenient for controling quality and favourable to large-scale industrialization and continuous production.
Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend \>70% of the classes.
Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
PCT No. PCT/EP90/02042 Sec. 371 Date Jun. 12, 1992 Sec. 102(e) Date Jun. 12, 1992 PCT Filed Nov. 28, 1989 PCT Pub. No. WO91/09015 PCT Pub. Date Jun. 27, 1991.A series of novel 3-phenyl-3-(1-(cyclicalkyl)pyrrolidin-3-yl)glutarimide derivatives have been prepared, including their pharmaceutically acceptable salts. The cyclic moiety present in these compounds is derived from either benzene or a heteroaryl such as benzofuran or 2,3-dihydrobenzofuran, or it is derived from an aromatic heterocyclic such as pyridine, pyrazine or thiophene, and it is attached to the adjacent alkyl group of the molecule by means of one of the available ring carbon atoms situated in the aromatic ring of the aforementioned cyclic ring moiety. These particular compounds are useful in therapy as selective muscarinic receptor antagonists, which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites and therefore, are of value in the treatment of diseases associated with altered motility and/or smooth muscle tone as found in the gut, trachea and bladder. Methods for preparing these compounds from known starting materials are provided.
1. A vaccine for curing or preventing pneumococcal infection, containing polypeptide in a pharmaceutically acceptable carrier, characterised in that the above polypeptide contains alpha-spiral part, identical in at least 90 percent with SEQ ID no: 1 sequence and it does not contain choline-binding part. The amount of polypeptide in the above vaccine is the amount effective to cure or prevent the pneumococcal infection. 11. An antibody against polypeptide, containing alpha-spiral part, identical in at least 90 percent with SEQ ID no: 1 sequence, whereby the above polypeptide does not contain choline-binding part. 19. Use of a representative chosen from the group including: a) the vaccine defined in paragraph 1; and b) at least one antibody against an immunogen, which is a polypeptide, containing an amino acid sequence, identical in at least 90 percent with a sequence chosen from the group including the amino acid sequences SEQ ID NO:3 to SEQ ID NO:18 and which does not contain choline-binding part for producing a drug for preventing and/or curing pneumococcal infections in a body of the host. 20. An isolated polypeptide containing amino acid sequence, identical in at least 90 percent with a sequence chosen from the group including amino acid sequences SEQ ID NO:3 to SEQ ID NO:18, whereby the above polypeptide contains alpha-spiral part, identical in at least 90 percent with SEQ ID no: 1 sequence and does not contain choline-binding part.
This is a phase I/II, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a multivalent GBS vaccine candidate in healthy, non-pregnant, adult WOCBA, 18-49 years of age, at two sites, one each in the US and South Africa. Approximately 600 participants will be randomized to receive a single dose of low, mid, or high concentration of IVT GBS-06, or a placebo (saline control) at Day (D)1, administered IM by injecting 0.5 mL into the deltoid muscle. The three dose levels denote the amount of capsular polysaccharide (CPS) for each of the six serotypes per 0.5 mL. These four study groups will be enrolled simultaneously to allow for parallel assessments of overall IVT GBS-06 safety and tolerability. Participants will be randomized in a 1:1:1:1 ratio to one of the dose levels or placebo. This study will utilize a sentinel-cohort design in which 20 participants overall (i.e., N=5 per treatment arm) at the US site will be randomized, vaccinated, and evaluated for safety prior to opening enrolment of additional participants in USA and in South Africa. This study targets representation from both study populations and therefore at least 220 participants will be recruited from each of the two sites and will allow competitive enrollment across the two study sites for the remaining 160 participants to reach 600 within target enrollment period.
Patients being treated with etoposide must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with etoposide therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of etoposide: platelet count, hemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm 3 or an absolute neutrophil count below 500/mm 3 is an indication to withhold further therapy until the blood counts have sufficiently recovered. 

Physicians should be aware of the possible occurrence of an anaphylactic reaction manifested by chills, fever, tachycardia, bronchospasm, dyspnea, and hypotension. Higher rates of anaphylactic-like reactions have been reported in children who received infusions at concentrations higher than those recommended. The role that concentration of infusion (or rate of infusion) plays in the development of anaphylactic-like reactions is uncertain (see ADVERSE REACTIONS). Treatment is symptomatic. The infusion should be terminated immediately, followed by the administration of pressor agents, corticosteroids, antihistamines, or volume expanders at the discretion of the physician. 

For parenteral administration, Etoposide Injection, USP should be given only by slow intravenous infusion (usually over a 30- to 60-minute period) since hypotension has been reported as a possible side effect of rapid intravenous injection.